The United States Food and Drug Administration has approved use of the combination of BRAF and MEK inhibitors for BRAF V600E mutant malignant melanomas, anaplastic thyroid cancers, non-small cell lung cancers, pediatric low grade gliomas requiring systemic therapy and metastatic unresectable solid tumors as a tissue agnostic treatment. This evidence concerns the gene BRAF and central nervous system cancer.